Engflag

Almacon

Quick links to important sections

Almacon

Almacon_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Almacon

Quick Facts

Property Description
Active Ingredients Aluminium Hydroxide, Magnesium Hydroxide, Simethicone
Form Oral Suspension (Liquid)
Pharmacological Class Antacid and Anti-flatulent Combination
Common Purpose Relief from acid indigestion and gas-related discomfort
Origin Mineral Salts (Inorganic) and Synthetic Polymer

What Type of Medication is Almacon?

Almacon is defined as a non-systemic combination product administered orally, belonging to the Antacid and Anti-flatulent Combination class. This pharmacological classification identifies it as a medication formulated to address digestive distress arising from two distinct causes: excess stomach acid and the physical presence of intestinal gas. Combination antacids, such as those utilizing these specific salts, are clinically recognized for providing effective symptomatic relief from hyperacidity. The medication is delivered as an Oral Suspension, which is a liquid form allowing for rapid dispersal across the mucosal lining of the upper digestive system.

The Composition and Form: A Triad of Active Agents

The preparation’s core composition comprises three active ingredients: the inorganic salts Aluminium Hydroxide and Magnesium Hydroxide, and the synthetic agent Simethicone (Simeticone). The hydroxides are alkaline compounds that act locally to neutralize stomach acid, while Simethicone is an inert silicone compound used for its physical effects on gas. The decision to combine both aluminum and magnesium salts is a crucial formulation strategy intended to stabilize bowel activity, mitigating the potential for the individual components to cause changes in motility. The balancing of these two mineral components provides a more tolerable relief profile.

General Purpose: Targeting Acid and Gas Discomfort

The general purpose of Almacon is to provide effective, localized relief by targeting the two main issues simultaneously. It helps mitigate the burning sensation associated with acid irritation through chemical buffering, while the anti-flatulent effect of Simethicone addresses symptoms like pressure, bloating, and fullness. The antifoaming mechanism of Simethicone physically reduces the surface tension of gas bubbles to aid their passage. This combined approach offers a broad initial scope for symptomatic relief by directly impacting both the chemical and physical sources of upper gastrointestinal discomfort.

Regulatory References

  1. Antacids
  2. Simethicone Mechanism of Action

What side effects are possible with Almacon?

Possible Side Effects and Safety Information

The safety profile for Almacon, a combination of Aluminium Hydroxide, Magnesium Hydroxide, and Simethicone, is documented by regulatory authorities primarily based on the actions of the mineral antacid components.

Officially Classified Adverse Reactions

The most frequently documented effects relate to Gastrointestinal Disorders, reflecting the product's localized action. These include changes in bowel habits, with Diarrhoea (linked to magnesium) and Constipation (linked to aluminum) being the most commonly reported, often classified as Uncommon.

Other adverse reactions are reported within the following System-Organ Classes:

  • Immune System Disorders: Including Hypersensitivity reactions, which are typically listed with a frequency of Not Known.
  • Metabolism and Nutrition Disorders: These are rare but serious and include Hypermagnesemia and Hypophosphatemia.

Serious Adverse Reactions and Safety Constraints

The most serious documented safety concerns are systemic and are directly related to the accumulation of the active ingredients, mainly occurring in specific patient populations or under chronic use conditions. These include:

  • Aluminum Toxicity (e.g., encephalopathy, dementia) and Hypermagnesemia (high magnesium levels in the blood), which are explicit risks for individuals with Renal Impairment (kidney disease). Use is strictly constrained in patients with impaired renal function due to the failure to clear these minerals.
  • Hypophosphatemia (low blood phosphate) and associated Osteomalacia (bone softening) are documented risks linked to Prolonged Administration or excessive intake of the aluminum component.
  • The medication carries a high-level safety note that it can alter the absorption of other orally administered drugs, requiring separation of dosing times.

This structure ensures that the safety information is presented with clear boundaries, separating common localized effects from the systemic and duration-dependent risks defined in official regulatory labeling.

Overdose and Emergency Response

Overdose and when to seek help

Regulatory labeling indicates that acute overdose may present with documented gastrointestinal manifestations, primarily diarrhoea, abdominal pain, and vomiting. Official regulatory statements note that serious systemic symptoms are unlikely following a single acute overdosage.

Systemic Complications and High-Risk Exposure

The most critical documented risks are tied to long-term, high-dose exposure or use in patients with compromised elimination. The active mineral salts may lead to systemic accumulation, resulting in Hypermagnesemia, Hyperaluminemia, and Hypophosphatemia. In patients with renal function deficiency, prolonged high-dose exposure carries the risk of severe neurological and metabolic outcomes, including encephalopathy, dementia, and microcytic anemia. Large doses may also trigger or aggravate intestinal obstruction and ileus in high-risk populations such as the elderly or those with existing renal impairment.

Mandated Emergency Actions and Management

Official regulatory guidance mandates that patients seek emergency medical attention or contact a Poison Help line immediately if overdose is suspected. The documented treatment for acute overdose involves supportive measures such as rehydration and forced diuresis. Intravenous Calcium Gluconate is an officially described intervention used to counteract severe Hypermagnesemia. For any patient with renal function deficiency, the regulatory management dictates that haemodialysis or peritoneal dialysis is necessary to eliminate accumulated mineral salts.

Therapeutic Uses of Almacon

What Almacon Treats: Main Uses and Benefits

Almacon is applied across therapeutic domains involving certain distressing symptoms associated with upper gastrointestinal tract irritation. The use of this combination antacid aligns with established classification for antacids combined with anti-flatulents for the management of concurrent symptoms of gas and acid indigestion. It is generally used to provide supportive relief for symptoms related to heightened physiological activity, such as heartburn (pyrosis), acid indigestion, and the uncomfortable sensation of acid regurgitation.

This medication is relevant for easing symptom clusters that may become intense or disruptive, including abdominal bloating, physical pressure, and uncomfortable fullness linked to trapped gas. It is commonly used across conditions presenting with acute or episodic manifestations, such as functional dyspepsia and common gastrointestinal distress often triggered by dietary factors. Applying the medication during these phases supports the patient by helping ease the overall symptom burden and contributes to day-to-day comfort.

Quick Fact: Symptomatic Relief Focus
Primary Goal Provides support that helps ease the overall symptom burden of acid and gas.
Conditions Used in situations involving recurrent or episodic manifestations of acid indigestion and dyspepsia.
Symptom Scope Helps address symptom clusters that may become intense or disruptive (burning, bloating, fullness).

Eligibility and Restrictions for Use

Who Can and Cannot Use Almacon?

Almacon’s eligibility is strictly defined by government regulatory labeling, establishing who may use the medication and who must not.

Absolute Contraindications and Required Consultations

Use of Almacon is contraindicated for individuals with a known hypersensitivity or allergy to any of its active ingredients: Aluminium Hydroxide, Magnesium Hydroxide, or Simethicone. Due to the risk of mineral accumulation, the medicine is also contraindicated in patients with Severe Chronic Kidney Disease.

Consultation with a healthcare professional is explicitly required before use for several populations:

  • Patients with kidney disease or those on a magnesium-restricted diet.
  • Individuals who have stomach bleeding or obstruction.
  • Women who are pregnant or breast-feeding.

Age and Duration Restrictions

The medication is approved for self-medication in adults and children 12 years of age and older. Use in children under 12 years of age is restricted and must be directed by a physician. Furthermore, the label stipulates a mandatory limitation on duration: the maximum dose must not be used for more than two weeks unless advised by a healthcare professional.

What should I know about interactions with other medicines?

Almacon, an antacid containing aluminum hydroxide and magnesium hydroxide, can significantly affect the absorption and efficacy of many other oral medications. The main mechanism is the binding of these antacid components to other drugs in the digestive tract, preventing them from being fully absorbed into the body.

To minimize potential interactions, it is generally recommended to separate the administration of Almacon from other oral medicines by at least two hours (taking the other medicine two hours before or two hours after the antacid).

Key medications whose absorption may be reduced by Almacon include:

  • Certain antibiotics: Particularly tetracyclines (e.g., doxycycline) and fluoroquinolones (e.g., ciprofloxacin, levofloxacin).
  • Thyroid hormones: Such as levothyroxine.
  • Oral glucocorticoids: Including prednisone and prednisolone.
  • Bisphosphonates: Used to treat osteoporosis.

In addition to drug-drug interactions, the aluminum component of Almacon can interact with products containing citrate (citric acid), found in many fruit juices and some effervescent drug formulations. Citrate can increase the absorption of aluminum, raising the risk of aluminum toxicity, especially in individuals with reduced kidney function. Patients with kidney impairment should consult a healthcare provider before using this product. Always inform your doctor or pharmacist about all prescription and non-prescription medicines, vitamins, and herbal products you are taking.

Mechanism of Action

Chemical Buffering and Proteolytic Inactivation

The core mechanism involves the Aluminum and Magnesium Hydroxides acting as local bases, initiating a rapid acid-base reaction to consume excess Hydrochloric Acid ( HCl) within the stomach lumen. This instantaneous elevation of pH not only consumes H^+ ions but also drives the pH-dependent inactivation of pepsin. The pH elevation supports the functional deactivation of this proteolytic enzyme. The physiological consequence is a rapid pH shift in the gastric chemical environment.

Modulating Intraluminal Gas Dynamics

The second domain of action is purely physical, exerted by Simethicone, which functions as a surfactant. This agent targets the surface tension of liquid-gas interfaces within the digestive tract, causing the numerous small foam bubbles to lose structural integrity and coalesce. This mechanical action transforms the trapped foam into larger, free gas pockets, facilitating their expulsion via normal physiological processes.

Functional Compensation of Motility

A crucial mechanistic synergy exists between the two metal hydroxide components. The combination of Aluminium Hydroxide, which has an inherent tendency to slow bowel movement, and Magnesium Hydroxide, which tends to accelerate it, results in a physiologically neutral effect on intestinal motility. The functional balancing contributes to a more neutral effect on intestinal motility compared to the individual salts.

Dosage and Administration Information

How to Use Almacon: Administration Guidelines

Almacon, a combination antacid and anti-flatulent (Aluminium Hydroxide, Magnesium Hydroxide, Simethicone), is designated for oral administration as a liquid suspension. The high-level usage pattern is standardized to ensure the active ingredients are delivered optimally for symptomatic relief.

Dosing and Frequency

Feature Usage Guideline
Route and Form Oral Suspension, taken by mouth.
Standard Adult Dose A single dose of 10 mL to 20 mL is typically administered. The total intake must not exceed 80 mL in a 24-hour period.
Timing and Schedule The suspension is generally taken after meals and at bedtime, or as required, with a maximum frequency of four times a day.
Duration of Use Usage is intended for short-term relief. The maximum recommended dosage should not be used continuously for more than two weeks without consulting a health professional.

Administration Requirements

Before administration, the oral suspension must be shaken well to ensure a uniform mixture of the active components. The required dose volume should be accurately measured using a designated dosing cup or spoon. For adults and children aged 12 years and older, the standard adult regimen applies. Due to potential impacts on absorption, it is advised to separate the intake of this antacid from other orally administered medications by at least two hours. The overall protocol dictates a non-systemic, time-bound regimen intended for episodic use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Almacon

Evidence for Symptoms of Heartburn and Acid Indigestion

The evidence base for this medication's components includes short-term randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time, comparing antacid formulations against an inactive substance or other acid-reducing medication classes. Studies have described patterns where antacid components were observed to increase stomach pH rapidly. Findings describe patterns observed in the studies related to patients reporting a temporary reduction in acute burning sensations. Regulatory status is derived from the Over-the-Counter (OTC) Monograph for antacids, reflecting the established evidence base for the drug class.

Evidence for Symptoms of Bloating, Pressure, and Gas

The anti-flatulent component, Simethicone, was studied for outcomes related to physical discomfort like abdominal pressure and bloating. Research has explored this component through RCTs and systematic reviews. Studies focused on episodes where symptoms become more noticeable, particularly for patients reporting gas and distension. This physical effect was studied in diagnostic procedures, where patterns of observation were noted to evaluate its effect on reducing gas and foam for visualization. However, findings were mixed when evaluating the component’s observed patterns for general bloating across all studies, and overall certainty remains low for a broad range of gas-related conditions.

Study Durations and Key Limitations

The research base is characterized by studies observing responses over defined time intervals that are typically short. Short-term RCTs provided the foundational data for regulatory acceptance of the antacid components. As a result, long-term effects are not fully established for either ingredient, and there is limited information for long-term outcomes related to the continued, daily use of this combination product. Data for certain groups, such as children, remain insufficient, and overall, the sample sizes were relatively small in some of the specific combination trials. Research provides context but not individual predictions about who will experience the most reported relief.

Key Studies & References

  1. Meta-analysis: the efficacy of over-the-counter gastro-oesophageal reflux disease therapies
  2. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management | NICE Guideline (CG184)

How should Almacon be stored and disposed of?

How to Store and Dispose of Almacon?

This section outlines the official, labeled requirements for the safe storage and regulated disposal of Almacon oral suspension, as defined by government regulatory authorities.

Official Storage Requirements

Storage Component Requirement Constraint
Temperature Store at controlled room temperature (20^circ to 25 C). Do not freeze.
Container Integrity Keep in the original container with the lid tightly closed. Protect from excess light and moisture.
Security Keep out of the sight and reach of children and pets. Must be stored in a safe, dry place.

Disposal Instructions

Unused or expired Almacon must be discarded according to regulatory guidelines. The preferred method is to utilize an official medicine take-back program.

Regulatory instructions specify that the suspension must not be flushed down the toilet or disposed of in wastewater to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Almacon found in:

A-Z Index: